Most cancers are curable when found early.
Most are not found early.
AETERNO exists to change that.
Metabolically active tumour tissue generates sustained heat above surrounding healthy tissue — a physiological fact documented in clinical thermography research since the 1960s. AETERNO maps surface and near-surface thermal signatures across the entire body, detecting asymmetric heat patterns that deviate from bilateral baseline.
Malignant cells shed specific proteins and glycoproteins into the bloodstream regardless of tumour depth or location. These serum biomarkers — measurable in a standard blood draw — provide a systemic window into oncological processes occurring anywhere in the body, from the surface to the deepest visceral organs.
Where thermal imaging sees the heat of malignancy on the surface, blood biomarkers detect the molecular signature of disease in the deep body. Together, they cover what neither can alone — this is the AETERNO Oncology Signal.
Select zones where you have detected or been told about abnormal warmth, asymmetry, or a physician has noted thermal irregularity.
Enter values from your laboratory report. Leave blank if not tested. Reference ranges shown per marker.
Each card shows which detection method applies and the primary serum markers associated. Dual-vector coverage means both thermal and blood signals can contribute to the anomaly score.
The strongest case for combined detection. Breast thermography is the most validated thermal oncology application — angiogenic tumour activity elevates skin temperature measurably. CA 15-3 rises with tumour burden. Together, both vectors contribute.
PSA remains the most widely used cancer biomarker in clinical practice. Elevated or rising PSA signals — particularly velocity over time — are the primary detection tool for prostate malignancy before symptoms emerge.
The thyroid sits directly beneath the skin of the anterior neck — making it one of the most thermally accessible organs in the body. Nodular thyroid tissue with increased vascularity produces a detectable thermal signature before clinical palpation.
CEA elevation in a non-smoker with no other explanation calls for colonoscopy referral. CA 19-9 co-elevation suggests spread to regional lymph nodes or liver. Trend monitoring over 3–6 month intervals is more informative than a single reading.
Ovarian cancer is notoriously silent until advanced stages. CA-125 elevation — especially in post-menopausal women — combined with symptoms like bloating or pelvic pressure calls for gynaecological evaluation. This is where early blood monitoring saves lives.
Melanoma and basal cell carcinoma generate measurable surface heat signatures above surrounding tissue. Thermal asymmetry of a pigmented lesion is a recognised early indicator worth monitoring. LDH elevation in advanced melanoma reflects systemic spread.
Pancreatic cancer has the lowest survival rate of any major cancer — largely because it is almost never caught early. CA 19-9 monitoring in high-risk individuals (family history, chronic pancreatitis, diabetes onset after 50) is one of the few available early-signal tools.
Alpha-fetoprotein elevation is strongly associated with hepatocellular carcinoma, particularly in patients with chronic hepatitis B/C or cirrhosis. AFP combined with liver function markers (ALT, AST) from a standard blood panel creates a meaningful early-warning picture.
Testicular cancer is one of the most treatable cancers when caught early — and one of the most accessible for combined detection. Thermal asymmetry between testes is a recognised early biometric indicator. AFP and beta-hCG are the primary tumour markers, often dramatically elevated at diagnosis.
CEA elevation in a current or former smoker calls for chest imaging review. NSE is elevated in small-cell lung cancer. CYFRA 21-1 correlates with non-small-cell histology. No single marker is conclusive, but pattern detection across multiple values raises signal confidence.
Enlarged lymph nodes generate detectable regional thermal elevation — axillary, cervical, and inguinal chains are thermally accessible. LDH elevation is a recognised risk-stratification marker in lymphoma. Early node detection through bilateral thermal comparison is clinically plausible.
Oral squamous cell carcinoma generates focal heat detectable thermally before it becomes visible or palpable. The jaw, floor of mouth, and tongue are thermally accessible. Persistent unexplained focal warmth in the oral region calls for ENT or maxillofacial evaluation.
CA-125 and HE4 together form the ROMA algorithm, a validated risk stratification tool for gynaecological malignancies. Endometrial cancer, when caught before spread beyond the uterus, has a 5-year survival rate exceeding 95%.
Cancer thermography is grounded in a well-documented physiological mechanism: rapidly dividing malignant cells increase local metabolic demand, triggering angiogenesis — the formation of new microvascular networks to sustain tumour growth. This vascular activity raises surface and near-surface tissue temperature measurably above bilateral baseline, creating a reproducible thermal signature in anatomically accessible cancers including breast, thyroid, skin, and testicular tissue.
Serum biomarker science operates through an entirely independent pathway. Malignant cells shed specific glycoproteins and antigens — CA-125, PSA, CEA, AFP, CA 19-9 — into the bloodstream in quantities proportional to tumour burden. These circulating proteins are detectable through standard venous blood draws at concentrations that often precede anatomical mass formation visible on imaging. Their value multiplies when tracked longitudinally: velocity and trend carry more information than any single result.
The strategic case for combining both vectors is rooted in their complementary blind spots. Thermal imaging cannot detect deep visceral tumours; blood biomarkers cannot localise surface anomalies or identify laterality. Together, they extend detection coverage across both anatomical planes — superficial and systemic — forming an early-warning architecture more sensitive than either method in isolation. This complementarity is the scientific foundation of the AETERNO Oncology Signal.
"Infrared thermography detects physiological changes associated with tumour angiogenesis before anatomical mass becomes visible on conventional imaging."
— Oncology thermography research literature"Tracking tumour marker velocity and trend over serial measurements provides substantially more information than any single elevated value in isolation."
— Clinical oncology biomarker practice guidelines"Stage at diagnosis remains the single greatest determinant of cancer survival — shifting detection from Stage IV to Stage I changes 5-year outcomes by 50 to 75 percentage points."
— European Cancer Information System, outcomes dataAETERNO Oncology Signal is a biometric anomaly monitoring system. It does not diagnose, screen, or classify cancer. All outputs are early-warning signals requiring clinical evaluation. It does not constitute a medical device under EU MDR 2017/745.
Signal scoring is algorithm-based and deterministic — not a black-box AI model. All scoring logic is disclosed. No output should be interpreted as clinical probability. Users are always directed to qualified oncologists for evaluation of any signal.
Tumour marker values entered into this module are classified as Special Category health data under GDPR Article 9. All processing is local to the user's session. No values are transmitted, stored, or shared. Zero data retention.